Highlighting New Treatments and Strategies for Acute Myeloid Leukemia and Acute Lymphocytic Leukemia
Jennie Goble, DMSc, PA-C, Mayo Clinic, Rochester, Minnesota, presented an update on breakthroughs in leukemia, focusing on emerging molecular targets and precision therapies in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) at the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress APP Institute in New York, New York.
The session emphasized how targeted treatments and precision medicine approaches are improving outcomes while aiming to reduce toxicity and enhance quality of life for patients with leukemia.
Transcript:
Hi, I am Jennie Goble. I'm a physician assistant at Mayo Clinic in Rochester, Minnesota. I'm here at LL&M Congress APP Institute, and I'm giving a talk on breakthroughs in leukemia.
My talk focuses on the molecular markers and new targets in AML and ALL. We'll talk about the targeted treatments in AML, including FLT3, IDH, and menin inhibitors, and the importance of hypomethylating agents and venetoclax in AML, as well as the importance of MRD monitoring in both AML and ALL.
We'll talk about upfront use of immunotherapy in ALL—also, how the use of precision medicine that is becoming more forefront in both AML and ALL, and how we're trying to decrease the organ toxicity in these leukemia patients in order to try to help their quality of life.
[We’ll also highlight how] moving forward how we're using all of these targeted agents in all these brand new drugs that are coming to the market, and the future of medicine for leukemia treatment.
Source:
Goble J. Breakthroughs in Leukemia: Evolving Frontlines and Beyond. Presented at Lymphoma, Leukemia & Myeloma Congress APP Institute; October 18, 2025. New York, NY.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.
The NP/PA Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!
